Heterogeneity in EGFR Mutations: Explaining a "Mixed Response" to EGFR TKIs in Patients with a Reported Mutation


One of the questions that comes up fairly frequently is what to make of a "mixed response" to systemic therapy: after several weeks or months of treatment, a scan shows some areas of known disease shrinking, but others are growing.  Why might this happen? What does it mean? And what should it lead us to do?

Subscribe to ROS1 rearrangement